AbbVie and Genmab’s would-be blockbuster epcoritamab has been recommended for conditional approval in the EU as a treatment for diffuse large B-cell lymphoma (DLBCL), an aggressive form of non-Hodgkin ...
Johnson & Johnson shares fell Tuesday despite a mostly strong second-quarter earnings report and an increase to its full-year guidance. We're not rattled by the market reaction and believe the reasons ...
After returning from surgery, my abdominal pain was zero. I never thought a life without this much pain could be so comfortable. Still, I continued with Humira. I got used to the self-injections, and ...
Javascript must be enabled to use this site. Please enable Javascript in your browser and try again. AARP NOW Get the app that makes your AARP membership truly mobile ...
The business of providing outsourced patient support and hub services is growing in lockstep with the growth of specialty pharmaceuticals, which are now approaching nearly half of pharma spending in ...
Biologics help reduce symptoms and prevent flare-ups in Crohn’s disease. Biologics are made up of large molecules from living things. Monoclonal antibodies are a common type of biologic used for Crohn ...
Florida's first known execution occurred in 1827, and the state later adopted the electric chair in 1923. Under Gov. Ron DeSantis, Florida set a new record in 2025 with 19 executions in a single year.
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth –– ARCALYST 2026 expected net ...
FDA approved a subcutaneous furosemide autoinjector with IV-equivalent exposure for edema in adults with HF or CKD, expanding the Furoscix franchise beyond the on-body infusor. Rapid administration ...
Early treatment can help relieve symptoms and protect joint function from arthritis in your fingers. Symptoms of finger arthritis often include stiffness, decreased grip strength, and swelling around ...
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
– ARCALYST 2026 expected net product revenue increased to $980 - $995 million – – KPL-387 Phase 2 data demonstrated rapid and sustained reductions in pain and inflammation at 300 mg SC once-monthly, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results